Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation

Fig. 6

CircSHKBP1 promotes GC growth in vivo. a and b. Xenograft tumors of nude mice 24 days after injection of BGC823 LV3-NC, LV3-sh1 or LV3-sh2 cells (n = 6 per group). Tumor weight and body weight were measured at the end point. c and d. Xenograft tumors of nude mice 21 days after injection of BGC823 LV5-NC or LV5-circSHKBP1 cells with or without the bevacizumab treatment (n = 6 per group). Tumor weight and body weight were measured at the end point. e and f Western blot showing the expression of HUR and VEGF in tumors (e) and serum VEGF (f) of LV5-NC and LV5-circSHKBP1 mice with or without bevacizumab treatment (tubulin and GAPDH as internal controls, respectively). g and h Western blot showing the expression of HUR and VEGF in tumors (g) and serum VEGF (h) of LV3-NC, LV3-sh1 and LV3-sh2 mice (tubulin and GAPDH as internal controls, respectively). i and j. IHC of VEGF and HUR in tumors of different groups. k and l. AOD of VEGF and HUR staining in tumors of different groups. m. Correlation of circSHKBP1 expression between xenograft tumors and serum exosomes of mice (R2 = 0.4758, P = 0.0044). n. Correlation of circSHKBP1 and miR-582 expression in xenograft tumors (R2 = 0.4706, P = 0.0047). o and p. IF of CD31 in xenograft tumors of LV5-NC and LV5-circSHKBP1 mice with or without bevacizumab treatment. The relative fluorescence of CD31 was measured by ImageJ. Quantitative data from three independent experiments are shown as the mean ± SD (error bars). *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test)

Back to article page